98%
921
2 minutes
20
The aim is to estimate the overall one-year survival rate and readmission rate after the first myocardial infarction. A cohort study involving 689 patients followed up between August 2016 and March 2022. The Kaplan-Meier estimator and the log-rank test were used. Cox semiparametric model was used to estimate death and readmission risk. The mean age was 60.0 (SD 11.0) years old, 67.9% men and 50.7% with ST-elevation myocardial infarction. The overall survival rate was 96.3%, with median time of death of 41.5 days. The readmission-free survival rate was 83.4%, with median time of readmission of 54 days. Age of 60 years and over increased death risk by 10.01 and the presence of systemic arterial hypertension increased readmission risk by 1.52. The overall survival rate was 96.2% with difference in age groups. The readmission-free survival rate was 83.4%, with difference by the presence of systemic arterial hypertension. As these events are quite prevalent, a better assessment of the effectiveness of the health care provided and the actions that must be taken to reduce the incidence and consequent morbidity and mortality is necessary.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1590/1413-81232025303.08212023 | DOI Listing |
Ann Palliat Med
September 2025
Brown University Health Cancer Institute, Providence, RI, USA; Division of Geriatrics and Palliative Medicine, Department of Medicine, Alpert Medical School of Brown University, Providence, RI, US.
ancreatic cancer is an aggressive disease and often presents at an advanced stage with no curative options. The disease is often characterized by rapid progression, limited or short-lived responsiveness to standard therapies, and a profound impact on patients' quality of life. Despite advances in targeted therapies and immunotherapy, curative outcomes remain elusive for the majority of patients with advanced or high-grade disease with a 5-year survival rate of less than 10%.
View Article and Find Full Text PDFJ Chemother
September 2025
Department of Medical Oncology, Hacettepe University, Ankara, Turkey.
Background: Well-differentiated (WDLPS) and dedifferentiated liposarcomas (DDLPS) are subtypes with distinct behaviors, often driven by CDK4 amplification. While CDK4/6 inhibitors such as palbociclib show promise in trials, real-world data are scarce.
Methods: We retrospectively analyzed 21 patients with advanced WDLPS or DDLPS treated with palbociclib monotherapy at 16 Turkish Oncology Group centers (2019-2022).
Dig Endosc
September 2025
Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Japan.
Objectives: Salvage endoscopic therapy is increasingly recommended for localized, superficial failure at the primary site after chemoradiotherapy for esophageal squamous cell carcinoma. This multicenter retrospective study aimed to evaluate the clinical outcomes and prognostic factors associated with overall survival in patients who underwent salvage endoscopic therapy for cT1N0M0 local failure after chemoradiotherapy or radiotherapy for esophageal squamous cell carcinoma.
Methods: We retrospectively analyzed patients with cT1N0M0 local failure after chemoradiotherapy or radiotherapy who underwent endoscopic resection or photodynamic therapy using talaporfin sodium at two Japanese institutions between 2012 and 2021.
Cerebrovasc Dis Extra
August 2025
Introduction: Trousseau syndrome (TS) represents a significant vascular thromboembolic event in cancer patients and has progressively gained attention as a critical clinical concern in recent years. The aim of this study is to investigate the survival status and prognostic factors in patients with TS whose initial clinical manifestation was acute ischemic stroke (AIS).
Methods: A retrospective analysis was conducted on 24 TS patients hospitalized at the Affiliated Hospital of Jiangsu University between 2018 and 2024.
Biochem Genet
September 2025
Department of Medical Biology, Cerrahpasa Faculty of Medicine, Istanbul University Cerrahpasa, Kocamustafapasa, 34098, Istanbul, Turkey.
Glioblastoma is the most aggressive and malignant tumor of the central nervous system. Current treatment options, including surgical excision, radiotherapy, and chemotherapy, have Limited efficacy, with a median survival rate of approximately 15 months. To develop novel therapeutics, it is crucial to understand the underlying molecular mechanisms driving glioblastoma.
View Article and Find Full Text PDF